FDA Approves POLIVY — Genentech, Inc.

# FDA Approves Genentech's POLIVY (polatuzumab vedotin) for Intravenous Administration Genentech's FDA approval of POLIVY (polatuzumab vedotin) marks the company's entry into the targeted oncology market with an antibody-drug conjugate therapeutic, positioning it to capture share in the growing immuno-oncology segment. The intravenous treatment expands Genentech's hematologic malignancy portfolio and strengthens its competitive stance against rival biologics in the cancer immunotherapy space.